Načítá se...
Impact of Renal Impairment on the Pharmacokinetics of Apremilast and Metabolite M12
The pharmacokinetics of apremilast and its major metabolite M12 were evaluated in subjects with varying degrees of renal impairment. Men and women with renal impairment (estimated glomerular filtration rate, 60‒89 mL/min [mild, n = 8], 30‒59 mL/min [moderate, n = 8], or <30 mL/min [severe, n = 8]...
Uloženo v:
| Vydáno v: | Clin Pharmacol Drug Dev |
|---|---|
| Hlavní autoři: | , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
John Wiley and Sons Inc.
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5132082/ https://ncbi.nlm.nih.gov/pubmed/27870479 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpdd.256 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|